首页|德国肺癌个性化治疗的实施

德国肺癌个性化治疗的实施

扫码查看
原文链接
  • 万方数据
  • 维普
网络基因组医学(network genomic medicine,NGM)是利用基于二代测序的多重分子诊断来寻找有潜在治疗意义的基因组畸变.德国NGM肺癌项目致力于在常规临床实践中有效地实施个体化的肺癌治疗.该项目不断发展,目前已包括德国约300家转诊机构,并已将多重分子检测纳入了德国主要医疗保险公司的常规报销范围.目前德国每年有超过5000例肺癌患者(约占德国肺癌患者的10%)接受基因分型.NGM的高通量分子诊断方法可对许多患者进行常规检测,使该项目能够有竞争力地参与改变全球临床实践的试验,而且还可以启动多中心临床试验.德国NGM肺癌项目建立了个体化的早期概念验证临床试验平台,包括针对所有可靶向突变的临床试验.德国的国家网络基因组医学(nNGM)肺癌项目于2018年启动.nNGM的理念是将NGM模式扩展到德国全国,从而为晚期肺癌患者提供高度创新的分子诊断和治疗.基于二代测序的分子诊断技术目前已经覆盖了65%的德国晚期肺癌患者.nNGM是目前在复杂和多样化的医疗系统中快速实现创新肿瘤基因组医学的最佳实践范例.本研究介绍了德国NGM肺癌项目的概况,以及nNGM肺癌项目的成功经验,旨在为我国将个性化癌症治疗纳入临床常规提供参考.
Implementation of Personalized Lung Cancer Care in Germany
Network genomic medicine(NGM)utilizes next-generation sequencing(NGS)based molecular multiplex diagnostics to look for genomic aberrations with potential therapeutic relevance.NGM Lung Cancer project in Germany works to implement personalized lung cancer care effectively in clinical routine.The network has grown constantly and currently includes about 300 referring institutions in Germany and molecular multiplex diagnostic is now routinely covered by major German health insurance companies.Currently,more than 5000 lung cancer patients(about 10%of lung cancer patients in Germany)are genotyped every year.The high throughput molecular diagnostics approach allows routine testing of many patients and enables it to competitively participate in global practice changing trials and to initiate multicenter trials.NGM Lung Cancer established a personalized early proof of concept clinical trial platform including clinical trials for all targetable mutations.The initiative of the National Network Genomic Medicine(nNGM)Lung Cancer started in 2018.The idea of nNGM is to extend the NGM model nationwide and thus to create access to highly innovative molecular diagnostics and innovative therapy for patients with advanced lung cancer.Currently,NGS-based molecular diagnostics has already covered for 65%of the German patients with advanced lung cancer.nNGM represents a best practice example now for rapid implementation of innovative genomic cancer medicine in clinical routine in a complex and diversified health care system.This article introduces the overview of the NGM Lung Cancer project in Germany and the successful experience of the nNGM Lung Cancer initiative,aiming to provide reference for integrating personalized cancer therapy into clinical routine in China.

Lung cancerPersonalized medicineNetwork genomic medicineCentralized detection-decentralized treatmentNext-generation sequencing based molecular multiplex diagnostics

杜利、王闻雅

展开 >

清华大学附属北京清华长庚医院医学研究中心,北京 102218

肺癌 精准医疗 网络基因组医学 集中检测-分散治疗 基于二代测序的多重分子诊断

国家重点研发计划"政府间国际科技创新合作"重点专项中国-欧盟国际精准医疗领域合作支持计划(IC2PerMed)

2021YFE0192400

2024

中国医药导刊
国家食品药品监督管理局信息中心

中国医药导刊

影响因子：1.408
ISSN：1009-0959
年,卷(期)：2024.26(1)
  • 27